Botanix Executive Chairman Vince Ippolito will be a featured presenter on Tuesday, 9 September at the HC Wainwright 27th Annual Global Investment Conference in New York, NY (US). This conference attracts institutional fund managers from around the world and some of the most promising global growth companies, including those in the healthcare and life sciences sectors.
Botanix Chief Executive Officer Dr Howie McKibbon will be a featured presenter at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, which attracts institutional fund managers from around the world, and some of the most promising global growth companies, including those in the healthcare and life sciences sectors, will present during the event.
Botanix CEO Howie McKibbon will be a featured presenter at ASX Small and Mid-Cap Conference on Wednesday, 25 September, and the E&P Small Cap Healthcare Conference on Thursday, 26 September. Botanix will also conduct one-on-one updates with investors.
Click here to view ASX Release.
Video is now available of the Company’s Commercial Day Webinar recorded on 17 September. In the presentation, the Botanix commercial team and their guests provide market insights and a comprehensive update on the launch plans for Sofdra™.
Video is now available of the Company’s Commercial Day Webinar presented on 8 May.
The expanded commercial team provides market insights and a comprehensive update on commercial launch plans for Sofdra™, which is expected to be approved in late June 2024.
Botanix (ASX: BOT) has received a communication from FDA in relation to its NDA submission for Sofpironium Bromide gel, 15% (SB) for the treatment of primary axillary hyperhidrosis.
Encouragingly, no clinical efficacy, safety or manufacturing issues were raised and no additional clinical studies are required by the FDA to support approval. We will be revising the printed Instructions for Use document proposed for inclusion with the product and our team is now focused on working with the FDA to address the points raised, with plans to resubmit the NDA for SB by 1Q CY24 and targeting approval for mid-CY24.
Earlier today Botanix hosted an investor webinar outlining details of the Response Letter from the FDA – and next steps for approval. The team was joined by Mr Dave Clissold, Director of Hyman, Phelps & McNamara – the largest dedicated FDA law firm in the United States advising pharmaceutical, biotechnology, medical device, food, and dietary supplement clients on regulatory matters.
Botanix (ASX: BOT) hosted a webinar recently to update investors on the Company’s progress during the FDA review period for its lead product, Sofpironium Bromide.
The webinar was hosted by Executive Director, Matt Callahan and Chief Operating Officer, Howie McKibbon.
Take a look.
Botanix (ASX: BOT) hosted a webinar to update shareholders on the Company’s preparations for the FDA mid-cycle review of Sofpironium Bromide in Q1 2023.
The webinar was hosted by Gautam Aggarwal, a Partner with Triangle Insights Group, who has conducted insightful market research in relation to the Sofpironium Bromide.
Other presenters included Botanix Executive Director, Matt Callahan and Botanix Chief Operating Officer, Dr Howie McKibbon.
Botanix Executive Director, Matt Callahan, recently participated in the ShareCafe Small Cap ‘Hidden Gems’ Webinar.
His presentation provided an overview of our clinical pipeline, including the significant potential for new dermatology products and opportunities for adding new assets to our pipeline. Matt also shared an update on upcoming clinical and operational milestones for 2022.
Botanix has today released an updated corporate presentation to the ASX, to support a non-deal investor roadshow underway this week.
The latest developments in our antimicrobial resistance (AMR) and dermatology R&D programs, include:
